While driving down an East Texas country road I spotted this scene. The autumn trees and the late afternoon sun made these golden bales of hay shine just a little bit more. Fortunately I had my camera with me. (c) James Q. Eddy Jr.
The Four States NPR News Source 2025 Kansas Association of Broadcasters Award Winner 2nd Place for Website in a Medium Market
Play Live Radio
Next Up:
0:00
0:00
0:00 0:00
Available On Air Stations
Stream and Listen To KRPS's Weekday Morning & Afternoon Newscasts In The NPR App

The FDA Just Approved A Major Alzheimer’s Drug. Now What?

Biogen is the maker of aducanumab, which has been the source of much debate amongst Alzheimer's experts.
Biogen is the maker of aducanumab, which has been the source of much debate amongst Alzheimer's experts.

On Monday, the FDA approved aducanumab, a new medication for Alzheimer’s.

It’s the first new drug for the disease in almost two decades and the first to attack the disease process itself, instead of just its symptoms.

But the FDA’s approval comes despite an intense debate over the drug’s efficacy and associated side effects.

From Kaiser Health News:

We discuss what we know about aducanumab and how it will shape the future of Alzheimer’s research and treatment.

Copyright 2021 WAMU 88.5

Kathryn Fink
Kathryn Fink is a producer with NPR's All Things Considered.